Home
Plasma
Plasma Protein Therapies
Safety & Quality
Standards Programs
IQPP
QSEAL
Regulatory Policy
Pathogen Safety
Donor History Questionnaire
National Donor Deferral Registry (NDDR®)
North America Programs
Patient Notification System
North America Data Program
European Programs
European Distribution Data
Meetings & Events
Plasma Protein Forum
Sponsorship & Exhibitor Opportunities
International Plasma Protein Congress
Global Plasma Summit
International Plasma Awareness Week
Media Center
Partners
PPTA Business Forum
PPTA Regulatory Workshop
Brussels Times Event
Events Calendar
About Us
About PPTA
Boards of Directors
European Plasma Alliance
PPTA France
Current Members
Join PPTA
Code of Ethics
Membership Levels
Staff
The Source magazine
Subscribe to The Source
Contact Us
Submit Your Question
Topics
Access to Care
Overview
U.S. Federal
U.S. State
Canada
Europe
Resource Center
Plasma FAQs
Advocacy
Publications & Presentations
Media
Newsroom
PPTA Portal
Home
Plasma
Plasma Protein Therapies
Safety & Quality
Standards Programs
IQPP
QSEAL
Regulatory Policy
Pathogen Safety
Donor History Questionnaire
National Donor Deferral Registry (NDDR®)
North America Programs
Patient Notification System
North America Data Program
European Programs
European Distribution Data
Meetings & Events
Plasma Protein Forum
Sponsorship & Exhibitor Opportunities
International Plasma Protein Congress
Global Plasma Summit
International Plasma Awareness Week
Media Center
Partners
PPTA Business Forum
PPTA Regulatory Workshop
Brussels Times Event
Events Calendar
About Us
About PPTA
Boards of Directors
European Plasma Alliance
PPTA France
Current Members
Join PPTA
Code of Ethics
Membership Levels
Staff
The Source magazine
Subscribe to The Source
Contact Us
Submit Your Question
Topics
Access to Care
Overview
U.S. Federal
U.S. State
Canada
Europe
Resource Center
Plasma FAQs
Advocacy
Publications & Presentations
Media
Newsroom
PPTA Portal
Sitemap
Immunoglobulin Access
Immunoglobulin Access Materials
Mainmenu
Home
Plasma
Plasma Protein Therapies
Safety & Quality
Standards Programs
IQPP
QSEAL
Regulatory Policy
Pathogen Safety
Donor History Questionnaire
National Donor Deferral Registry (NDDR®)
North America Programs
Patient Notification System
North America Data Program
European Programs
European Distribution Data
Meetings & Events
Plasma Protein Forum
Sponsorship & Exhibitor Opportunities
International Plasma Protein Congress
Global Plasma Summit
International Plasma Awareness Week
Media Center
Partners
PPTA Business Forum
PPTA Regulatory Workshop
Brussels Times Event
Events Calendar
About Us
About PPTA
Boards of Directors
European Plasma Alliance
PPTA France
Current Members
Join PPTA
Code of Ethics
Membership Levels
Staff
The Source magazine
Subscribe to The Source
Contact Us
Submit Your Question
Topics
Access to Care
Overview
U.S. Federal
U.S. State
Canada
Europe
Resource Center
Plasma FAQs
Advocacy
Publications & Presentations
Media
Newsroom
PPTA Portal
Membership Menu
Join PPTA
Membership Levels
Benefits of Membership
Current Members
Plasma Products Database Menu
Albumin
Immunoglobulin
Alpha 1-anti-trypsin
Clotting Factors
Media and Information Menu
PPTA Statements
Facts and Figures
Videos
Press Contact
The Source magazine
Advocacy Menu
Advocacy Toolkit
Patient Notification System
Patient Organizations
Access to Care
Patient Information Resources
Bottommenu
Membership
Benefits of Membership
Current Members
Plasma Products Databases
Albumin
Immunoglobulin
Alpha-1 Antitrypsin
Clotting Factors
Media and Information
Press Releases
PPTA Statements
Fact Sheets
Videos
Press Contact
Advocacy
Advocacy Toolkit
Patient Notification System
Patient Organizations
Access to Care
Patient Information Resources
Code of Ethics
Hidden Menu
Terms of Use
Privacy Policy
Sitemap
Event Booking
PDF Viewer
Flipbook test
Uncategorized
Brussels Times Event
PPTA Executive Summary of FDA’s U.S. Immunoglobulin Utilization Study Report
PPTA Portal
Standards Programs
Upcoming events
Recent Correspondence with Regulators in the U.S. and EU
Patient Information Resources
Submit Your Question
Plasma
Who Needs Plasma Therapies?
Plasma
Plasma Protein Therapies
Plasma Protein Therapies
Therapies
Quality and Standards
Pathogen Safety
PPTA Donor History Questionnaire
National Donor Deferral Registry (NDDR®)
Quality Standards of Excellence, Assurance and Leadership (QSEAL)
International Quality Plasma Program (IQPP)
Safety and Quality
Meetings and Events
Plasma Protein Forum 2023
International Plasma Protein Congress (IPPC) 2023
PPTA Business Forum
Sponsorship & Exhibitor Opportunities
Global Plasma Summit
Regulatory Workshop
2013 Conferences and Symposiums
IPAW
IPAW Partners
IPAW Media Center
International Plasma Awareness Week (IPAW)
PPTA Business Forum
PPTA Business Forum registration open!
About Us
Contact Us
Staff
Boards of Directors
About PPTA
Privacy Policy
Terms of Use
Topics
Access to Care | Ontario
Overview
Communication & Advocacy
Regulatory Policy
Final Therapies
Regulatory Policy
Regions
Membership
Benefits of Membership
Membership Levels
Member Code of Ethics
Join PPTA
Membership
Current Members
Current Members
Plasma Products Database
Media and Information
Press Contact
Videos
Subscribe to The Source
Emergency Preparedness
The Source
Fact Sheets
Press Releases
A missed opportunity to acknowledge EU’s dependency on U.S. plasma
International Plasma Awareness Week 2022: Donate Locally. Think Globally.
Adoption of the EP report “EU Pharmaceutical Strategy”
Calling on EU Policymakers to Increase Plasma Donations
International Plasma Awareness Week 2021: Donate Plasma. Save Lives.
EU Health Commissioner says plasma donation plays a vital role
Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
Treatments for rare diseases at risk, due to the decline of plasma donations
Inception Impact Assessment Underlines the Need for Timely Action to Decrease the Reliance on Third Countries for Plasma
International Plasma Awareness Week 2020: Be a Hero, Donate Plasma Today
EU Health Commissioner Says Plasma Donation is “More Important Than Ever”
New Edition of EDQM Blood Guide Risks Decreasing European Plasma Collection
PPTA Applauds Administration for Focus on Plasma Donation
Plasma-Derived Therapies Provide Significant Health Value Gain
PPTA encourages EDQM to take a patient-centric approach in the implementation of its Plasma Supply Management Recommendations
PPTA Welcomes New Executive Director of European Division
PPTA Names Amy Efantis President & CEO
PPTA Recognizes Essential Contributions of Plasma Donors
GLOBAL INITIATIVE DRAWS ATTENTION TO RARE DISEASE TREATMENTS
Rep. Matsui Recognizes International Plasma Awareness Week
International Plasma Awareness Week: Plasma Donors are the Foundation
David Bell Elected Chair of PPTA Global Board of Directors
Patient Organizations and Industry Join Together to Celebrate Third Annual International Plasma Awareness Week
PPTA Celebrates International Plasma Awareness Week
Alabama Lowers Minimum Donation Age to 18
PPTA Recognizes World Hemophilia Day–April 17, 2015
PPTA Recognizes 8th Annual International Rare Disease Day
Ensuring Access to Medicines for Patients: Pharmaceutical Industry Associations Release ‘Principles for Communication of Information on Quality and Manufacturing Potential Supply Disruption’
International Plasma Awareness Week to Celebrate Donors and Spotlight Rare Diseases
PPTA Recognizes World Hemophilia Day 2014
PPTA Recognizes First Plasma Collection Centers Certified in Hungary
PPTA Letter to Stakeholders re: European Data Program Update
PPTA Letter to Stakeholders re: European Data Program
Plasma Protein Therapeutics Industry to Convene in Denver
Patient Organizations Join Forces with Industry
Industry, Donors and Patients to Convene in Vienna
Plasma Donors and Rare Diseases Take Center Stage
PPTA Staff Honored with the Distinguished Alumni Award
PPTA Applauds Preserving Access to Orphan Drugs Acts
Discoveries and Developments: Highlights of the Plasma Protein Forum (June 2013)
PPTA and Member Companies Demonstrate Sustained Commitment to Patient Safety (June 26, 2013)
PPTA and Six Organizations Oppose NJ Tax on Clotting Factor (June 27, 2013)
PPTA Recognizes World Hemophilia Day
PPTA Statement: Effects of Sequester on Plasma Protein Therapies
PPTA Recognizes International Rare Disease Day 2013
Kedrion CEO Assumes Board Helm of PPTA
PPTA applauds the House of Representatives for Passing Milestone IVIG Access Act
Plasma Collection Continues to Gain Traction in Czech Republic
PPTA Presents at the European Haemophilia Consortium
PPTA Presents at ESID 2012
PPTA's 2012 Plasma Protein Forum
Celebrating PPTA's 20th Anniversary
First Internationally Certified Plasma Collection Center in Czech Republic
In Memoriam of Dr. Otto Schwarz
PPTA Honored in House of Representatives
PPTA Comments to FDA
PPTA Recognizes World Hemophilia Day
PPTA Recognizes International Rare Disease Day 2012
PPTA Letter to Stakeholders re: North America Data Program
PPTA Letter to Stakeholders re: North America Data Program
California State Assemblymember Atkins Honored At PPTA's Business Forum
PPTA Attends FDA Public Workshop on Drug Shortages
Californians And Floridians Recognized For Role In Helping Rare Disease Patients Who Need Lifesaving Therapies
ConQuaestor Report Confirms Cross Subsidies Within Sanquin
IRS Proposed Regulations on Orphan Drug Exclusion from Drug Tax Stand to Harm Future Development of Treatments for Rare Disease Patients
PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
PPTA Praises Legislation that Protects the Treatment of Rare Diseases
PPTA Opposes Tax on Blood Clotting Factor
PPTA Industry Expert Invited To Serve On HHS Advisory Committee On Blood Safety And Availability
PPTA Hosts Discussion Forum on Blood/Plasma Products in The Hague
PPTA Applauds the Florida Legislature for Preserving Medicaid Patient Access to Blood Clotting Factor
PPTA Commends Congress and President Obama for Repealing the 1099 Tax-reporting Provision
New Spanish Language Translations Available on PPTA Websites
PPTA Hosts Congressional Staff Briefing
PPTA Statement: Proven Safety of Human Albumin
Patient Organizations and Industry Join Together to Celebrate Fourth Annual International Plasma Awareness Week
Statements
PPTA Statements
PPTA Statement on Report of ENVI Rapporteur for the SoHO Regulation
PPTA Statement on the Ukraine Crisis
PPTA Leadership Update – Amy Efantis
PPTA Disagrees with Ruling from Romanian Competition Council
Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs
Study Shows Immunoglobulin Therapy is “Critical and Cost-Effective” in Treating CVID
PPTA Responds to ProPublica Article
Human Plasma Donations Remain Important During COVID-19 Pandemic
PPTA Statement on Immunoglobulin Use to Meet Clinical Need
PPTA Statement on the Inauguration of President Biden
Yes, you can donate source plasma after getting the COVID vaccine
PPTA Statement on Alberta’s Passing of the Voluntary Blood Donation Repeal Act
PPTA Statement on the Urgent Need for Plasma Donation
Plasma Donors Should be Celebrated, not Denigrated
New York and California recognize the importance of plasma donation
PPTA Testifies at USITC COVID-19 Related Goods Hearing
PPTA Opposes Executive Order That Would Threaten Access to Plasma Protein Therapies
PPTA Repeats Appeals for Plasma Donations
White House Roundtable: “We’re in this Together”
PPTA Responds to July 24 White House Executive Orders
Wall Street Journal: Letter to the Editor
PPTA Encourages Plasma Donation
PPTA Reacts to Huffington Post Article
PPTA Statement on FDA Guidance Documents
PPTA Responds to The Guardian Article
Letter to CMS to Allow Home Infusion COVID
A Note to European Plasma Donors on the Spread of Coronavirus
PPTA Responds to ARD Documentary
A Note to U.S. Plasma Donors on the Spread of Coronavirus
New Coronavirus (SARS-CoV-2) and the Safety Margins of Plasma Protein Therapies
PPTA Statement on H.R. 3
PPTA Responds to Newsweek Article
PPTA Responds to New York Times Article
PPTA Comments on Time Magazine Article
Statement on Romanian Competition Council
Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA)
PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans”
Plasma protein product safety and Creutzfeldt-Jakob disease (CJD)
Statement from Jan M. Bult, President & CEO, Plasma Protein Therapeutics Association
PPTA is Proud to Support Rare Disease Day 2017
PPTA Statement on the Documentary “Das Geschäft mit dem Blut”
PPTA Recognizes World PI Week: April 22-29, 2016
PPTA Recognizes World Hemophilia Day–April 17, 2016
FDA Releases Final Guidance on MSM Deferral Policy
PPTA Letter to Stakeholders re: North America Data Program
PPTA Letter to Stakeholders re: European Data Program Update
PPTA Statement on Review of Donor Blood Pressure Requirements
PPTA Statement on Review of Donor Weight Loss Monitoring
PPTA Statement on Management of Donors and Units that Test Positive for Hepatitis B Virus (HBV) DNA by Nucleic Acid Tests (NAT)
PPTA Statement on Current Considerations on Plasma Obtained from Whole Blood Donors for Further Manufacturing Use
Statement on Update on Safety of Albumin
PPTA Stat ement on the Rare Bleeding Disorders Workshop
PPTA Statement on Clinical and Surrogate Endpoints for Evaluating Efficacy of Alpha 1-Proteinase Inhibitor (Human) Augmentation Therapy
Dengue Virus and Plasma Protein Therapies
Human Parvovirus PARV4 and plasma protein therapies
Citrate Anticoagulant and Apheresis Perspective of Plasma Protein Therapeutics Industry
PPTA Statement on Safety of Plasma Protein Therapies and the H5N1 Virus es
Statement on the Safety of Plasma Protein Therapies and Swine Influenza Virus
PPTA Statement on MSM Donor Policy
PPTA Statement: Effects of Sequester on Plasma Protein Therapies
PPTA Statement: Proven Safety of Human Albumin
PPTA Comments on the IQWiG Rapid Report on Haemophilia Therapies
PPTA Statement on Signing of Health Care Reform Bill
Ebola Virus and Plasma Protein Therapies
PPTA's Updated Response to Ontario's Proposal to Ban Compensated Plasma Donation
Zika Virus and Plasma Protein Therapies
Advocacy
Patient Organizations
Patient Notification System (PNS)
Advocacy Toolkit
Access to Care
European Plasma Alliance
FAQs: Source and Recovered COVID-19 Plasma Donors are Essential
Novel Coronavirus Disease (COVID-19) Resources
Immunoglobulin Access Materials
Access to Care | U.S. State
Access to Care | U.S. Federal
A propos de PPTA France
Donor Stories
Patient Stories
United Kingdom
The Netherlands
Germany
Belgium
Austria
Access to Care | Europe
News
PPTA News
PPTA Welcomes Anita Brikman as New Chief Executive Officer
Brussels Times Event Held in European Parliament
Register now for the International Plasma Protein Congress (IPPC) 2023
Extension of EU/US MRA to Include PDMPs Is a Positive Step Forward
HHS Launches Plasma and Blood Donation Campaign
PPTA Statement on the draft EU Substances of Human Origin Regulation
Monkeypox Virus and Plasma Protein Therapies
Announcing PPTA’s New Global Chair
PPTA's 2021 Annual Report Now Available
The Telegraph continues maligning plasma donors
Transfusion publishes scientific paper regarding viral safety of plasma-derived therapeutics
Fabrizio Fabbrizzi – 10 April 1955 - 2 January 2020
PPTA Letter to American National Red Cross
PPTA Statement on Immunoglobulin Access
Immunoglobulin Access
PPTA Highlights Importance of Patient Access to Plasma Protein Therapies
Donor ethics letter submitted to the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada
PPTA Responds to The Pharmaceutical Journal
PPTA is concerned that the U.S. Senate is considering legislation that would move control over essential health benefits to all 50 states
The U.S. Senate will try to move forward shortly on a “motion to proceed” to debate on repeal of the Affordable Care Act
Endangering Patient's Access to Care: Proposals to Repeal the Affordable Care Act
PPTA Proudly Supports World Hemophilia Day 2017
The Hilfenhaus Award conferred to Prof. Farkas at the IPPC 2017
PPTA Remembers John W. Walsh
PPTA Remembers Corey Dubin
PPTA Supports 9th Annual International Rare Disease Day
Vale - Guelfo Marcucci – Father of Italian fractionation
New Study Shows Increased Development of Inhibitors using Recombinant Factor VIII
New Supplement Addresses Hemolytic Complications of IVIG Infusions
PPTA Mourns Passing of Dr. Víctor Grífols Lucas
Initiation of the Five Week Enrollment Period for the Medicare IVIG Demonstration Project
EHC Video on European Recommendations for Haemophilia Treatment
Restrictive Coverage Policies and Patient Access
Vaccine Recommendations for Patients with PI
PPTA Announcement: DLA Piper to Provide Federal Legislative Representation
PPTA's Response to Ontario's Proposal to Ban Compensated Plasma Donation
IN MEMORIAM: MENSO BULT
Rare Disease Day Congressional Tele-Town Hall
IN MEMORIAM THEO EVERS
PPTA Recognizes International Rare Disease Day 2014
PPTA Strengthens Global Brand
FDA Request to Cease Blood Collection in Florida
Ethical Considerations in Compensated Plasma Donation
PPTA Chosen to Join Mission to China
Source Plasma News
International Plasma Awareness Week infographics available for your use!
Regulatory Policy News
Final Summary of the PPTA/FDA Liaison Meeting on September 14, 2022
Final Summary of the PPTA-FDA Liaison Meeting: October 7, 2021
PPTA Works with Federal Regulators in the U.S.
Final Summary FDA Liaison Meeting: November 18, 2020
Public Workshop Focuses on Immune Globulin Products
FDA Posts Public Meeting Documents
115th meeting of the FDA Blood Products Advisory Committee
PPTA Presents at ACBTSA Meeting
PPTA Attends the 114th Meeting of the FDA Blood Products Advisory Committee (BPAC)
BPAC Meets to Hear Research Program Updates
PPTA Co-Sponsors Public Workshop
PPTA Staff Honored with the Distinguished Alumni Award
FDA Launches New Quality/Compliance Web Content
PPTA Participates in Health Canada Roundtable
FDA Announces Meeting Date: Blood Products Advisory Committee
Meetings and Events News
Save the Date for IPAW 2022!
BioPlasma World Asia 2013
Patient Access News
Global Access News
Free Trade News
PlasmaLit Database Updates
Distribution Data
European Distribution Data
European Distribution Data
European Distribution Data
European Distribution Data
European Distribution Data
European Distribution Data
European Distribution Data
North America Data Program
Resource Center
What We Know Now about the “Kawasaki-Like” Syndrome
What Does the COVID-19 Vaccine Mean for Plasma Donation?
Newsroom
Media
Publications & Presentations
Advocacy
Plasma FAQs
Media and Information
Press Releases
PPTA Statements
Fact Sheets
Emergency Preparedness
Videos
Press Contact
Advocacy
Advocacy Toolkit
Patient Notification System
Patient Organizations
Access to Care
Copyright © 2022 PPTA. All rights reserved. (202) 789-3100
Terms of Use
|
Privacy Statement
|
Sitemap